The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery
Open accessAbstract
Artificial intelligence (AI) has permeated various sectors, including the pharmaceutical industry and research, where it has been utilized to efficiently identify new chemical entities with desirable properties. The application of AI algorithms to drug discovery presents both remarkable opportunities and challenges. This review article focuses on the transformative role of AI in medicinal chemistry. We delve into the applications of machine learning and deep learning techniques in drug screening and design, discussing their potential to expedite the early drug discovery process. In particular, we provide a comprehensive overview of the use of AI algorithms in predicting protein structures, drug–target interactions, and molecular properties such as drug toxicity. While AI has accelerated the drug discovery process, data quality issues and technological constraints remain challenges. Nonetheless, new relationships and methods have been unveiled, demonstrating AI’s expanding potential in predicting and understanding drug interactions and properties. For its full potential to be realized, interdisciplinary collaboration is essential. This review underscores AI’s growing influence on the future trajectory of medicinal chemistry and stresses the importance of ongoing synergies between computational and domain experts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A. L., Fang, T., Doncheva, N. T., Pyysalo, S., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1000 · Cited by 9,726
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
UniProt: the Universal Protein Knowledgebase in 2023
The UniProt Consortium, Bateman, A., Martin, M.-J., Orchard, S., Magrane, M., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., Bye-A-Jee, H., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1052 · Cited by 7,210
Evolutionary-scale prediction of atomic level protein structure with a language model
Lin, Z., Akin, H., Rao, R., Hie, B., Zhu, Z., Lu, W., Smetanin, N., Verkuil, R., Kabeli, O., Shmueli, Y., et al. (2022) · doi:10.1101/2022.07.20.500902 · Cited by 5,990
I-TASSER server for protein 3D structure prediction
Zhang, Y. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-40 · Cited by 5,124
Protein complex prediction with AlphaFold-Multimer
Evans, R., O’Neill, M., Pritzel, A., Antropova, N., Senior, A., Green, T., Žídek, A., Bates, R., Blackwell, S., Yim, J., et al. (2021) · doi:10.1101/2021.10.04.463034 · Cited by 3,808
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac956 · Cited by 3,443
MoleculeNet: a benchmark for molecular machine learning
Wu, Z., Ramsundar, B., Feinberg, E. N., Gomes, J., Geniesse, C., Pappu, A. S., Leswing, K., & Pande, V. (2018) · Chemical Science · doi:10.1039/c7sc02664a · Cited by 3,107
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Research works printed but not linked: 205
- Chen, 2023, Artificial intelligence for drug discovery: Resources, methods, and applications, Mol. Ther. Nucl. Acids, 31, 691, 10.1016/j.omtn.2023.02.019 · DOI · Paper page
- Cifci, M.A. (2023). A Deep Learning-Based Framework for Uncertainty Quantification in Medical Imaging Using the DropWeak Technique: An Empirical Study with Baresnet. Diagnostics, 13. · DOI
- Wong, 2023, Deep Learning of Sparse Patterns in Medical IoT for Efficient Big Data Harnessing, IEEE Access, 11, 25856, 10.1109/ACCESS.2023.3256721 · DOI
- Alya, 2021, Artificial intelligence in drug design: Algorithms, applications, challenges and ethics, Future Drug Discov., 3, FDD59, 10.4155/fdd-2020-0028 · DOI
- Zhu, 2020, Big Data and Artificial Intelligence Modeling for Drug Discovery, Annu. Rev. Pharmacol., 60, 573, 10.1146/annurev-pharmtox-010919-023324 · DOI · Paper page
- Hu, 2019, Application of Machine Learning Approaches for the Design and Study of Anticancer Drugs, Curr. Drug Targets, 20, 488, 10.2174/1389450119666180809122244 · DOI
- Tong, 2021, Generative Models for De Novo Drug Design, J. Med. Chem., 64, 14011, 10.1021/acs.jmedchem.1c00927 · DOI · Paper page
- Cheng, 2021, Molecular design in drug discovery: A comprehensive review of deep generative models, Brief Bioinform., 22, bbab344, 10.1093/bib/bbab344 · DOI · Paper page
- Xue, 2019, Advances and challenges in deep generative models for de novo molecule generation, Wires Comput. Mol. Sci., 9, e1395, 10.1002/wcms.1395 · DOI
- Vemula, 2023, CADD, AI and ML in drug discovery: A comprehensive review, Eur. J. Pharm. Sci., 181, 106324, 10.1016/j.ejps.2022.106324 · DOI · Paper page
- Cerchia, 2023, New avenues in artificial-intelligence-assisted drug discovery, Drug Discov. Today, 28, 103516, 10.1016/j.drudis.2023.103516 · DOI
- Dara, 2022, Machine Learning in Drug Discovery: A Review, Artif. Intell. Rev., 55, 1947, 10.1007/s10462-021-10058-4 · DOI · Paper page
- Priya, 2022, Machine learning approaches and their applications in drug discovery and design, Chem. Biol. Drug Des., 100, 136, 10.1111/cbdd.14057 · DOI
- Guedes, 2021, New machine learning and physics-based scoring functions for drug discovery, Sci. Rep., 11, 3198, 10.1038/s41598-021-82410-1 · DOI · Paper page
- Tamura, 2023, Large-scale prediction of activity cliffs using machine and deep learning methods of increasing complexity, J. Cheminform., 15, 4, 10.1186/s13321-022-00676-7 · DOI
- Stumpfe, 2020, Advances in exploring activity cliffs, J. Comput. Aid. Mol. Des., 34, 929, 10.1007/s10822-020-00315-z · DOI
- Heikamp, 2012, Prediction of Activity Cliffs Using Support Vector Machines, J. Chem. Inf. Model, 52, 2354, 10.1021/ci300306a · DOI
- Bajorath, 2022, Evolution of Support Vector Machine and Regression Modeling in Chemoinformatics and Drug Discovery, J. Comput. Aid. Mol. Des., 36, 355, 10.1007/s10822-022-00442-9 · DOI · Paper page
- Warszycki, 2021, Pharmacoprint: A Combination of a Pharmacophore Fingerprint and Artificial Intelligence as a Tool for Computer-Aided Drug Design, J. Chem. Inf. Model, 61, 5054, 10.1021/acs.jcim.1c00589 · DOI
- Jayaraj, 2019, Ligand based virtual screening using SVM on GPU, Comput. Biol. Chem., 83, 107143, 10.1016/j.compbiolchem.2019.107143 · DOI
- Ogura, 2019, Support Vector Machine model for hERG inhibitory activities based on the integrated hERG database using descriptor selection by NSGA-II, Sci. Rep., 9, 12220, 10.1038/s41598-019-47536-3 · DOI
- Vogt, 2017, Support Vector Machine Classification and Regression Prioritize Different Structural Features for Binary Compound Activity and Potency Value Prediction, ACS Omega, 2, 6371, 10.1021/acsomega.7b01079 · DOI
- 2021, Epigenetic Target Profiler: A Web Server to Predict Epigenetic Targets of Small Molecules, J. Chem. Inf. Model, 61, 1550, 10.1021/acs.jcim.1c00045 · DOI
- Tong, 2019, Identifying potential drug targets in hepatocellular carcinoma based on network analysis and one-class support vector machine, Sci. Rep., 9, 10442, 10.1038/s41598-019-46540-x · DOI
- Kwon, S., Bae, H., Jo, J., and Yoon, S. (2019). Comprehensive ensemble in QSAR prediction for drug discovery. BMC Bioinform., 20. · DOI · Paper page
- Kaiser, 2018, A Machine Learning Approach for Predicting HIV Reverse Transcriptase Mutation Susceptibility of Biologically Active Compounds, J. Chem. Inf. Model, 58, 1544, 10.1021/acs.jcim.7b00475 · DOI
- Hu, J., Zhou, L.W., Li, B., Zhang, X.L., and Chen, N.S. (2021). Improve hot region prediction by analyzing different machine learning algorithms. BMC Bioinform., 22. · DOI
- Celebi, R., Uyar, H., Yasar, E., Gumus, O., Dikenelli, O., and Dumontier, M. (2019). Evaluation of knowledge graph embedding approaches for drug-drug interaction prediction in realistic settings. BMC Bioinform., 20. · DOI
- Cai, 2019, Deep Learning-Based Prediction of Drug-Induced Cardiotoxicity, J. Chem. Inf. Model, 59, 1073, 10.1021/acs.jcim.8b00769 · DOI · Paper page
- Madhukar, 2019, A Bayesian machine learning approach for drug target identification using diverse data types, Nat. Commun., 10, 5221, 10.1038/s41467-019-12928-6 · DOI · Paper page
- Saha, S., Chatterjee, P., Halder, A.K., Nasipuri, M., Basu, S., and Plewczynski, D. (2022). ML-DTD: Machine Learning-Based Drug Target Discovery for the Potential Treatment of COVID-19. Vaccines, 10. · DOI
- Khan, A.K.A., and Malim, N.H.A.H. (2023). Comparative Studies on Resampling Techniques in Machine Learning and Deep Learning Models for Drug-Target Interaction Prediction. Molecules, 28. · DOI
- Carpenter, 2018, Machine Learning-based Virtual Screening and Its Applications to Alzheimer’s Drug Discovery: A Review, Curr. Pharm. Des., 24, 3347, 10.2174/1381612824666180607124038 · DOI · Paper page
- Zakharov, 2016, QSAR Modeling and Prediction of Drug-Drug Interactions, Mol. Pharm., 13, 545, 10.1021/acs.molpharmaceut.5b00762 · DOI
- Cooper, 2021, Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning, ACS Omega, 6, 4857, 10.1021/acsomega.0c05303 · DOI
- Brekkan, 2019, Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM, J. Pharmacokinet. Pharmacodyn., 46, 591, 10.1007/s10928-019-09658-z · DOI
- Tamposis, 2019, Semi-supervised learning of Hidden Markov Models for biological sequence analysis, Bioinformatics, 35, 2208, 10.1093/bioinformatics/bty910 · DOI
- Nguyen, N.P., Nute, M., Mirarab, S., and Warnow, T. (2016). HIPPI: Highly accurate protein family classification with ensembles of HMMs. BMC Genom., 17. · DOI
- Li, J.F., Lee, J.Y., and Liao, L. (2021). A new algorithm to train hidden Markov models for biological sequences with partial labels. BMC Bioinform., 22. · doi:10.1186/s12859-021-04080-0
- Tamposis, 2019, JUCHMME: A Java Utility for Class Hidden Markov Models and Extensions for biological sequence analysis, Bioinformatics, 35, 5309, 10.1093/bioinformatics/btz533 · doi:10.1093/bioinformatics/btz533
- Kaur, 2023, Mapping the FtsQBL divisome components in bacterial NTD pathogens as potential drug targets, Front. Genet., 13, 1010870, 10.3389/fgene.2022.1010870 · DOI
- Gupta, 2021, Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening, J. Chem. Inf. Model, 61, 4236, 10.1021/acs.jcim.1c00710 · DOI
- Madugula, 2021, Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing, Comput. Biol. Med., 138, 104856, 10.1016/j.compbiomed.2021.104856 · DOI
- Huang, 2021, Drug-drug similarity measure and its applications, Brief Bioinform., 22, bbaa265
- Nedyalkova, M., and Simeonov, V. (2021). Partitioning Pattern of Natural Products Based on Molecular Properties Descriptors Representing Drug-Likeness. Symmetry, 13. · doi:10.3390/sym13040546
- McKay, 2022, Essential Dynamics Ensemble Docking for Structure-Based GPCR Drug Discovery, Front. Mol. Biosci., 9, 879212, 10.3389/fmolb.2022.879212 · DOI
- Chandak, 2020, Using machine learning to improve ensemble docking for drug discovery, Proteins, 88, 1263, 10.1002/prot.25899 · DOI
- Yang, 2022, Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy, Comput. Struct. Biotechnol. J., 20, 2442, 10.1016/j.csbj.2022.05.023 · DOI
- Andronov, 2021, Exploring Chemical Reaction Space with Reaction Difference Fingerprints and Parametric t-SNE, ACS Omega, 6, 30743, 10.1021/acsomega.1c04778 · DOI
- Barnard, 2020, Less may be more: An informed reflection on molecular descriptors for drug design and discovery, Mol. Syst. Des. Eng., 5, 317, 10.1039/C9ME00109C · DOI
- Liu, 2021, GraphDTI: A robust deep learning predictor of drug-target interactions from multiple heterogeneous data, J. Cheminform., 13, 58, 10.1186/s13321-021-00540-0 · DOI
- Xu, 2020, A t-SNE Based Classification Approach to Compositional Microbiome Data, Front. Genet., 11, 620143, 10.3389/fgene.2020.620143 · DOI
- Karagiannaki, I., Gourlia, K., Lagani, V., Pantazis, Y., and Tsamardinos, I. (2022). Learning biologically-interpretable latent representations for gene expression data. Mach. Learn., 1–31. · DOI
- Zhang, L.P., Tang, L., Zhang, S.L., Wang, Z.Z., Shen, X.H., and Zhang, Z.Q. (2021). A Self-Adaptive Reinforcement-Exploration Q-Learning Algorithm. Symmetry, 13. · doi:10.3390/sym13061057
- Tang, B.W., He, F.M., Liu, D.P., He, F., Wu, T., Fang, M.J., Niu, Z.M., Wu, Z., and Xu, D. (2022). AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2. Biomolecules, 12. · DOI
- Wang, 2020, Towards efficient discovery of green synthetic pathways with Monte Carlo tree search and reinforcement learning, Chem. Sci., 11, 10959, 10.1039/D0SC04184J · DOI
- Lee, G., Jang, G.H., Kang, H.Y., and Song, G. (2021). Predicting aptamer sequences that interact with target proteins using an aptamer-protein interaction classifier and a Monte Carlo tree search approach. PLoS ONE, 16. · DOI
- Yoshizawa, 2022, Selective Inhibitor Design for Kinase Homologs Using Multiobjective Monte Carlo Tree Search, J. Chem. Inf. Model, 62, 5351, 10.1021/acs.jcim.2c00787 · DOI
- Li, 2021, Structure-based de novo drug design using 3D deep generative models, Chem. Sci., 12, 13664, 10.1039/D1SC04444C · DOI · Paper page
- Genheden, 2020, AiZynthFinder: A fast, robust and flexible open-source software for retrosynthetic planning, J. Cheminform., 12, 70, 10.1186/s13321-020-00472-1 · DOI · Paper page
- Skalic, 2019, PlayMolecule BindScope: Large scale CNN-based virtual screening on the web, Bioinformatics, 35, 1237, 10.1093/bioinformatics/bty758 · DOI
- Haneczok, 2021, Machine learning enabled identification of potential SARS-CoV-2 3CLpro inhibitors based on fixed molecular fingerprints and Graph-CNN neural representations, J. Biomed. Inform., 119, 103821, 10.1016/j.jbi.2021.103821 · DOI
- Huo, 2023, An improved 3D quantitative structure-activity relationships (QSAR) of molecules with CNN-based partial least squares model, Artif. Intell. Life Sci., 3, 100065
- Qian, 2022, CAT-CPI: Combining CNN and transformer to learn compound image features for predicting compound-protein interactions, Front. Mol. Biosci., 9, 963912, 10.3389/fmolb.2022.963912 · DOI
- Jiang, 2019, FRSite: Protein drug binding site prediction based on faster R-CNN, J. Mol. Graph. Model., 93, 107454, 10.1016/j.jmgm.2019.107454 · DOI
- Hirohara, M., Saito, Y., Koda, Y., Sato, K., and Sakakibara, Y. (2018). Convolutional neural network based on SMILES representation of compounds for detecting chemical motif. BMC Bioinform., 19. · DOI · Paper page
- Hu, 2023, De novo drug design based on Stack-RNN with multi-objective reward-weighted sum and reinforcement learning, J. Mol. Model., 29, 121, 10.1007/s00894-023-05523-6 · DOI
- Chen, 2022, Recurrent neural network (RNN) model accelerates the development of antibacterial metronidazole derivatives, RSC Adv., 12, 22893, 10.1039/D2RA01807A · doi:10.1039/d2ra01807a
- Lim, 2019, Predicting Drug-Target Interaction Using a Novel Graph Neural Network with 3D Structure-Embedded Graph Representation, J. Chem. Inf. Model., 59, 3981, 10.1021/acs.jcim.9b00387 · DOI · Paper page
- Plisson, 2022, Natural product drug discovery in the artificial intelligence era, Chem. Sci., 13, 1526, 10.1039/D1SC04471K · DOI · Paper page
- Yang, 2017, Deep belief network-based drug identification using near infrared spectroscopy, J. Innov. Opt. Health Sci., 10, 1630011, 10.1142/S1793545816300111 · doi:10.1142/s1793545816300111
- Griffiths, 2020, Constrained Bayesian optimization for automatic chemical design using variational autoencoders, Chem. Sci., 11, 577, 10.1039/C9SC04026A · DOI · Paper page
- Sajadi, S.Z., Chahooki, M.A.Z., Gharaghani, S., and Abbasi, K. (2021). AutoDTI plus plus: Deep unsupervised learning for DTI prediction by autoencoders. BMC Bioinform., 22. · DOI
- Zhang, 2022, Drug-protein interaction prediction via variational autoencoders and attention mechanisms, Front. Genet., 13, 1032779, 10.3389/fgene.2022.1032779 · DOI
- Song, 2023, DNMG: Deep molecular generative model by fusion of 3D information for de novo drug design, Methods, 211, 10, 10.1016/j.ymeth.2023.02.001 · DOI
- Hussain, 2020, High-content image generation for drug discovery using generative adversarial networks, Neural Netw., 132, 353, 10.1016/j.neunet.2020.09.007 · DOI
- Yu, 2023, DGANDDI: Double Generative Adversarial Networks for Drug-Drug Interaction Prediction, IEEE/ACM Trans. Comput. Biol. Bioinform., 20, 1854, 10.1109/TCBB.2022.3219883 · DOI
- Zhao, 2020, GANsDTA: Predicting Drug-Target Binding Affinity Using GANs, Front. Genet., 10, 1243, 10.3389/fgene.2019.01243 · DOI
- Hicks, 2022, On evaluation metrics for medical applications of artificial intelligence, Sci. Rep., 12, 5979, 10.1038/s41598-022-09954-8 · DOI · Paper page
- Mendez, 2019, ChEMBL: Towards direct deposition of bioassay data, Nucleic Acids Res., 47, D930, 10.1093/nar/gky1075 · DOI · Paper page
- Irwin, 2020, ZINC20-A Free Ultralarge-Scale Chemical Database for Ligand Discovery, J. Chem. Inf. Model., 60, 6065, 10.1021/acs.jcim.0c00675 · DOI · Paper page
- Pence, 2010, ChemSpider: An Online Chemical Information Resource, J. Chem. Educ., 87, 1123, 10.1021/ed100697w · DOI · Paper page
- Avram, 2022, DrugCentral 2023 extends human clinical data and integrates veterinary drugs, Nucleic Acids Res., 51, D1276, 10.1093/nar/gkac1085 · DOI · Paper page
- Kanehisa, 2000, KEGG: Kyoto Encyclopedia of Genes and Genomes, Nucleic Acids Res., 28, 27, 10.1093/nar/28.1.27 · DOI · Paper page
- Karp, 2019, The BioCyc collection of microbial genomes and metabolic pathways, Brief Bioinform., 20, 1085, 10.1093/bib/bbx085 · DOI · Paper page
- Gillespie, 2022, The reactome pathway knowledgebase 2022, Nucleic Acids Res., 50, D687, 10.1093/nar/gkab1028 · DOI · Paper page
- Wishart, 2022, HMDB 5.0: The Human Metabolome Database for 2022, Nucleic Acids Res., 50, D622, 10.1093/nar/gkab1062 · DOI · Paper page
- Orchard, 2014, The MIntAct project-IntAct as a common curation platform for 11 molecular interaction databases, Nucleic Acids Res., 42, D358, 10.1093/nar/gkt1115 · DOI · Paper page
- Szklarczyk, 2016, STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data, Nucleic Acids Res., 44, D380, 10.1093/nar/gkv1277 · DOI · Paper page
- Gilson, 2016, BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology, Nucleic Acids Res., 44, D1045, 10.1093/nar/gkv1072 · DOI · Paper page
- Zhou, 2022, Therapeutic target database update 2022: Facilitating drug discovery with enriched comparative data of targeted agents, Nucleic Acids Res., 50, D1398, 10.1093/nar/gkab953 · DOI · Paper page
- Harding, 2022, The IUPHAR/BPS guide to PHARMACOLOGY in 2022: Curating pharmacology for COVID-19, malaria and antibacterials, Nucleic Acids Res., 50, D1282, 10.1093/nar/gkab1010 · DOI · Paper page
- Freshour, 2021, Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts, Nucleic Acids Res., 49, D1144, 10.1093/nar/gkaa1084 · DOI · Paper page
- Davis, 2022, Comparative Toxicogenomics Database (CTD): Update 2023, Nucleic Acids Res., 51, D1257, 10.1093/nar/gkac833 · DOI · Paper page
- Ganter, 2006, Toxicogenomics in drug discovery and development: Mechanistic analysis of compound/class-dependent effects using the DrugMatrix® database, Pharmacogenomics, 7, 1025, 10.2217/14622416.7.7.1025 · DOI
- Kuhn, 2016, The SIDER database of drugs and side effects, Nucleic Acids Res., 44, D1075, 10.1093/nar/gkv1075 · DOI · Paper page
- Blum, 2022, InterPro in 2022, Nucleic Acids Res., 51, D418
- Benson, 2012, GenBank, Nucleic Acids Res., 41, D36, 10.1093/nar/gks1195 · DOI · Paper page
- Burley, 2022, RCSB Protein Data Bank (RCSB.org): Delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence/machine learning, Nucleic Acids Res., 51, D488, 10.1093/nar/gkac1077 · DOI · Paper page
- Feng, 2004, Ligand Depot: A data warehouse for ligands bound to macromolecules, Bioinformatics, 20, 2153, 10.1093/bioinformatics/bth214 · DOI · Paper page
- Sorokina, 2021, COCONUT online: Collection of Open Natural Products database, J. Cheminform., 13, 2, 10.1186/s13321-020-00478-9 · DOI · Paper page
- Landaburu, 2020, TDR Targets 6: Driving drug discovery for human pathogens through intensive chemogenomic data integration, Nucleic Acids Res., 48, D992
- Bryant, 2023, Deep learning for protein complex structure prediction, Curr. Opin. Struct. Biol., 79, 102529, 10.1016/j.sbi.2023.102529 · DOI
- Ivankov, D.N., and Finkelstein, A.V. (2020). Solution of Levinthal’s Paradox and a Physical Theory of Protein Folding Times. Biomolecules, 10. · DOI
- Rose, 2021, Protein folding—Seeing is deceiving, Protein Sci., 30, 1606, 10.1002/pro.4096 · DOI
- Sorokina, I., Mushegian, A.R., and Koonin, E.V. (2022). Is Protein Folding a Thermodynamically Unfavorable, Active, Energy-Dependent Process?. Int. J. Mol. Sci., 23. · DOI
- Muhammed, 2019, Homology modeling in drug discovery: Overview, current applications, and future perspectives, Chem. Biol. Drug Des., 93, 12, 10.1111/cbdd.13388 · DOI · Paper page
- Burley, S.K., Berman, H.M., Duarte, J.M., Feng, Z.K., Flatt, J.W., Hudson, B.P., Lowe, R., Peisach, E., Piehl, D.W., and Rose, Y. (2022). Protein Data Bank: A Comprehensive Review of 3D Structure Holdings and Worldwide Utilization by Researchers, Educators, and Students. Biomolecules, 12. · DOI
- Burley, 2022, RCSB Protein Data Bank: Celebrating 50 years of the PDB with new tools for understanding and visualizing biological macromolecules in 3D, Protein Sci., 31, 187, 10.1002/pro.4213 · DOI · Paper page
- Sali, 1993, Comparative Protein Modeling by Satisfaction of Spatial Restraints, J. Mol. Biol., 234, 779, 10.1006/jmbi.1993.1626 · DOI · Paper page
- Webb, 2021, Protein Structure Modeling with MODELLER, Methods Mol. Biol., 2199, 239, 10.1007/978-1-0716-0892-0_14 · DOI · Paper page
- Studer, G., Tauriello, G., Bienert, S., Biasini, M., Johner, N., and Schwede, T. (2021). ProMod3—A versatile homology modelling toolbox. PLoS Comput. Biol., 17. · DOI · Paper page
- Studer, 2020, QMEANDisCo-distance constraints applied on model quality estimation, Bioinformatics, 36, 1765, 10.1093/bioinformatics/btz828 · DOI · Paper page
- Waterhouse, 2018, SWISS-MODEL: Homology modelling of protein structures and complexes, Nucleic Acids Res., 46, W296, 10.1093/nar/gky427 · DOI · Paper page
- Roy, 2010, I-TASSER: A unified platform for automated protein structure and function prediction, Nat. Protoc., 5, 725, 10.1038/nprot.2010.5 · DOI · Paper page
- Kryshtafovych, 2018, Evaluation of the template-based modeling in CASP12, Proteins, 86, 321, 10.1002/prot.25425 · DOI
- Zheng, 2021, Protein structure prediction using deep learning distance and hydrogen-bonding restraints in CASP14, Proteins, 89, 1734, 10.1002/prot.26193 · DOI
- Jumper, 2021, Applying and improving AlphaFold at CASP14, Proteins, 89, 1711, 10.1002/prot.26257 · DOI · Paper page
- Senior, 2020, Improved protein structure prediction using potentials from deep learning, Nature, 577, 706, 10.1038/s41586-019-1923-7 · DOI · Paper page
- Anishchenko, 2021, Protein tertiary structure prediction and refinement using deep learning and Rosetta in CASP14, Proteins, 89, 1722, 10.1002/prot.26194 · DOI
- Tourlet, 2023, AlphaFold2 Update and Perspectives, BioMedInformatics, 3, 378, 10.3390/biomedinformatics3020025 · DOI
- Sciacca, 2020, Lipid-Chaperone Hypothesis: A Common Molecular Mechanism of Membrane Disruption by Intrinsically Disordered Proteins, ACS Chem. Neurosci., 11, 4336, 10.1021/acschemneuro.0c00588 · DOI
- Fantini, 2003, How sphingolipids bind and shape proteins: Molecular basis of lipid-protein interactions in lipid shells, rafts and related biomembrane domains, Cell. Mol. Life Sci., 60, 1027, 10.1007/s00018-003-3003-1 · DOI
- Lee, 2022, Comparative studies of AlphaFold, RoseTTAFold and Modeller: A case study involving the use of G-protein-coupled receptors, Brief Bioinform., 23, bbac308, 10.1093/bib/bbac308 · DOI
- Tovar, 2007, Comparison of 2D fingerprint methods for multiple-template similarity searching on compound activity classes of increasing structural diversity, ChemMedChem, 2, 208, 10.1002/cmdc.200600225 · DOI
- Cedron, 2021, A review on machine learning approaches and trends in drug discovery, Comput. Struct. Biotech. J., 19, 4538, 10.1016/j.csbj.2021.08.011 · DOI · Paper page
- Ding, 2021, Molecular fingerprint-based machine learning assisted QSAR model development for prediction of ionic liquid properties, J. Mol. Liq., 326, 115212, 10.1016/j.molliq.2020.115212 · DOI
- Riniker, 2013, Open-source platform to benchmark fingerprints for ligand-based virtual screening, J. Cheminform., 5, 26, 10.1186/1758-2946-5-26 · DOI · Paper page
- Ojeda, 2015, Molecular fingerprint similarity search in virtual screening, Methods, 71, 58, 10.1016/j.ymeth.2014.08.005 · DOI · Paper page
- Gao, 2020, Are 2D fingerprints still valuable for drug discovery?, Phys. Chem. Chem. Phys., 22, 8373, 10.1039/D0CP00305K · DOI
- Rogers, 2010, Extended-Connectivity Fingerprints, J. Chem. Inf. Model., 50, 742, 10.1021/ci100050t · DOI · Paper page
- McGregor, 1999, Pharmacophore fingerprinting. 1. Application to QSAR and focused library design, J. Chem. Inf. Comput. Sci., 39, 569, 10.1021/ci980159j · DOI · Paper page
- Schwartz, 2013, SMIfp (SMILES fingerprint) Chemical Space for Virtual Screening and Visualization of Large Databases of Organic Molecules, J. Chem. Inf. Model., 53, 1979, 10.1021/ci400206h · DOI
- Awale, 2015, Stereoselective virtual screening of the ZINC database using atom pair 3D-fingerprints, J. Cheminform., 7, 3, 10.1186/s13321-014-0051-5 · DOI
- Da, 2014, Structural Protein-Ligand Interaction Fingerprints (SPLIF) for Structure-Based Virtual Screening: Method and Benchmark Study, J. Chem. Inf. Model., 54, 2555, 10.1021/ci500319f · DOI · Paper page
- Durant, 2002, Reoptimization of MDL keys for use in drug discovery, J. Chem. Inf. Comput. Sci., 42, 1273, 10.1021/ci010132r · DOI · Paper page
- (2023, July 22). PubChem Substructure Fingerprint, Available online: https://ftp.ncbi.nlm.nih.gov/pubchem/specifications/pubchem_fingerprints.pdf.
- Carhart, 1985, Atom Pairs as Molecular-Features in Structure Activity Studies—Definition and Applications, J. Chem. Inf. Comput. Sci., 25, 64, 10.1021/ci00046a002 · DOI · Paper page
- Bender, 2004, Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): Evaluation of performance, J. Chem. Inf. Comput. Sci., 44, 1708, 10.1021/ci0498719 · DOI · Paper page
- Schneider, 2016, De Novo Design at the Edge of Chaos, J. Med. Chem., 59, 4077, 10.1021/acs.jmedchem.5b01849 · DOI · Paper page
- Mouchlis, V.D., Afantitis, A., Serra, A., Fratello, M., Papadiamantis, A.G., Aidinis, V., Lynch, I., Greco, D., and Melagraki, G. (2021). Advances in De Novo Drug Design: From Conventional to Machine Learning Methods. Int. J. Mol. Sci., 22. · DOI · Paper page
- Girin, 2021, Dynamical Variational Autoencoders: A Comprehensive Review, Found. Trends Mach. Learn., 15, 1, 10.1561/2200000089 · DOI · Paper page
- Prykhodko, 2019, A de novo molecular generation method using latent vector based generative adversarial network, J. Cheminform., 11, 74, 10.1186/s13321-019-0397-9 · DOI · Paper page
- Sachdev, 2019, A comprehensive review of feature based methods for drug target interaction prediction, J. Biomed. Inform., 93, 103159, 10.1016/j.jbi.2019.103159 · DOI · Paper page
- Dhakal, 2022, Artificial intelligence in the prediction of protein-ligand interactions: Recent advances and future directions, Brief Bioinform., 23, bbab476, 10.1093/bib/bbab476 · DOI · Paper page
- Bissantz, 2010, A Medicinal Chemist’s Guide to Molecular Interactions, J. Med. Chem., 53, 6241, 10.1021/jm100950p · doi:10.1021/jm100950p
- Chen, 2016, Regulation of protein-ligand binding affinity by hydrogen bond pairing, Sci. Adv., 2, e1501240, 10.1126/sciadv.1501240 · DOI · Paper page
- Anusuya, 2018, Drug-Target Interactions: Prediction Methods and Applications, Curr. Protein Pept. Sci., 19, 537, 10.2174/1389203718666161108091609 · DOI
- Bagherian, 2021, Machine learning approaches and databases for prediction of drug-target interaction: A survey paper, Brief Bioinform., 22, 247, 10.1093/bib/bbz157 · DOI · Paper page
- Xu, 2021, Application of Machine Learning for Drug-Target Interaction Prediction, Front. Genet., 12, 680117, 10.3389/fgene.2021.680117 · DOI
- Yamanishi, 2008, Prediction of drug-target interaction networks from the integration of chemical and genomic spaces, Bioinformatics, 24, I232, 10.1093/bioinformatics/btn162 · DOI · Paper page
- Liu, 2015, Improving compound-protein interaction prediction by building up highly credible negative samples, Bioinformatics, 31, 221, 10.1093/bioinformatics/btv256 · DOI · Paper page
- Wang, 2021, GanDTI: A multi-task neural network for drug-target interaction prediction, Comput. Biol. Chem., 92, 107476, 10.1016/j.compbiolchem.2021.107476 · DOI
- Hecker, 2012, SuperTarget goes quantitative: Update on drug-target interactions, Nucleic Acids Res., 40, D1113, 10.1093/nar/gkr912 · DOI · Paper page
- Ding, 2022, Identification of drug-target interactions via multiple kernel-based triple collaborative matrix factorization, Brief Bioinform., 23, bbab582, 10.1093/bib/bbab582 · DOI
- Song, 2022, DeepFusion: A deep learning based multi-scale feature fusion method for predicting drug-target interactions, Methods, 204, 269, 10.1016/j.ymeth.2022.02.007 · DOI
- Yousefi, 2022, AttentionSiteDTI: An interpretable graph-based model for drug-target interaction prediction using NLP sentence-level relation classification, Brief Bioinform., 23, bbac272, 10.1093/bib/bbac272 · DOI
- Li, 2022, Effective drug-target interaction prediction with mutual interaction neural network, Bioinformatics, 38, 3582, 10.1093/bioinformatics/btac377 · DOI
- Xia, 2023, MDTips: A multimodal-data-based drug-target interaction prediction system fusing knowledge, gene expression profile, and structural data, Bioinformatics, 39, btad411, 10.1093/bioinformatics/btad411 · DOI
- Richard, 2016, ToxCast Chemical Landscape: Paving the Road to 21st Century Toxicology, Chem. Res. Toxicol., 29, 1225, 10.1021/acs.chemrestox.6b00135 · DOI · Paper page
- Dix, 2007, The ToxCast program for prioritizing toxicity testing of environmental chemicals, Toxicol. Sci., 95, 5, 10.1093/toxsci/kfl103 · DOI · Paper page
- 2020, In Silico ADME/Tox Profiling of Natural Products: A Focus on BIOFACQUIM, ACS Omega, 5, 16076, 10.1021/acsomega.0c01581 · DOI · Paper page
- Negus, 2018, Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination, Curr. Top Behav. Neurosci., 39, 245, 10.1007/7854_2016_36 · DOI
- Maltarollo, 2015, Applying machine learning techniques for ADME-Tox prediction: A review, Expert Opin. Drug Met., 11, 259, 10.1517/17425255.2015.980814 · DOI · Paper page
- Wenzel, 2019, Predictive Multitask Deep Neural Network Models for ADME-Tox Properties: Learning from Large Data Sets, J. Chem. Inf. Model., 59, 1253, 10.1021/acs.jcim.8b00785 · DOI · Paper page
- Almazroo, 2017, Drug Metabolism in the Liver, Clin. Liver Dis., 21, 1, 10.1016/j.cld.2016.08.001 · DOI · Paper page
- Xu, 2021, Research on the Species Difference of the Hepatotoxicity of Medicine Based on Transcriptome, Front. Pharmacol., 12, 647084, 10.3389/fphar.2021.647084 · DOI
- Bjornsson, 2015, Drug-induced liver injury: An overview over the most critical compounds, Arch. Toxicol., 89, 327, 10.1007/s00204-015-1456-2 · DOI
- Walker, 2020, The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development, Arch. Toxicol., 94, 2559, 10.1007/s00204-020-02763-w · DOI
- Takebe, 2018, The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development, Clin. Transl. Sci., 11, 597, 10.1111/cts.12577 · DOI · Paper page
- Clinton, 2021, Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature, Drug Saf., 44, 1125, 10.1007/s40264-021-01109-4 · DOI
- Ai, 2018, Predicting Drug-Induced Liver Injury Using Ensemble Learning Methods and Molecular Fingerprints, Toxicol. Sci., 165, 100, 10.1093/toxsci/kfy121 · DOI
- Li, 2022, Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future, Front. Cardiovasc. Med., 9, 966261, 10.3389/fcvm.2022.966261 · DOI
- Food and Drug Administration (2005). International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Fed. Regist., 70, 61133–61134.
- Lamothe, 2016, The Human Ether-a-go-go-related Gene (hERG) Potassium Channel Represents an Unusual Target for Protease-mediated Damage, J. Biol. Chem., 291, 20387, 10.1074/jbc.M116.743138 · DOI
- Babcock, 2013, hERG channel function: Beyond long QT, Acta Pharmacol. Sin., 34, 329, 10.1038/aps.2013.6 · DOI
- Pettersson, 2005, Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death, Eur. Heart J., 26, 590, 10.1093/eurheartj/ehi092 · DOI · Paper page
- Thomas, 2006, The cardiac hERG/I-Kr potassium channel as pharmacological target: Structure, function, regulation, and clinical applications, Curr. Pharm. Des., 12, 2271, 10.2174/138161206777585102 · doi:10.2174/138161206777585102
- Stergiopoulos, 2021, Prediction of hERG inhibition of drug discovery compounds using biomimetic HPLC measurements, ADMET DMPK, 9, 191
- Honma, 2020, An assessment of mutagenicity of chemical substances by (quantitative) structure-activity relationship, Genes Environ., 42, 23, 10.1186/s41021-020-00163-1 · doi:10.1186/s41021-020-00163-1
- Zhang, 2017, CarcinoPred-EL: Novel models for predicting the carcinogenicity of chemicals using molecular fingerprints and ensemble learning methods, Sci. Rep., 7, 2118, 10.1038/s41598-017-02365-0 · DOI · Paper page
- Basu, A.K. (2018). DNA Damage, Mutagenesis and Cancer. Int. J. Mol. Sci., 19. · DOI · Paper page
- Drevon, 1981, Mutagenicity Assays of Estrogenic Hormones in Mammalian Cells, Mutat. Res., 89, 83, 10.1016/0165-1218(81)90134-8 · DOI
- Ferguson, 2010, Chronic inflammation and mutagenesis, Mutat. Res. Fund. Mol. Mech. Mutagenes., 690, 3, 10.1016/j.mrfmmm.2010.03.007 · DOI
- Barnes, 2018, Carcinogens and DNA damage, Biochem. Soc. T, 46, 1213, 10.1042/BST20180519 · DOI · Paper page
- Fradkin, 2022, A graph neural network approach for molecule carcinogenicity prediction, Bioinformatics, 38, i84, 10.1093/bioinformatics/btac266 · DOI
- Bartsch, 1983, Comparison between Carcinogenicity and Mutagenicity Based on Chemicals Evaluated in the IARC Monographs, Environ. Health Persp., 47, 305, 10.1289/ehp.8347305 · DOI
- Knuiman, 1987, Inter-Laboratory Variability in Ames Assay Results, Mutat. Res., 180, 171, 10.1016/0027-5107(87)90212-0 · doi:10.1016/0027-5107(87)90212-0
- Galloway, 2017, International Regulatory Requirements for Genotoxicity Testing for Pharmaceuticals Used in Human Medicine, and Their Impurities and Metabolites, Environ. Mol. Mutagen., 58, 296, 10.1002/em.22077 · doi:10.1002/em.22077
- Li, 2022, DeepCarc: Deep learning-powered carcinogenicity prediction using model-level representation, Front. Artif. Intell., 4, 757780, 10.3389/frai.2021.757780 · DOI
- Zaslayskiy, 2019, ToxicBlend: Virtual screening of toxic compound with ensemble predictors, Comput. Toxicol., 10, 81, 10.1016/j.comtox.2019.01.001 · DOI
- Sharma, 2023, Accurate clinical toxicity prediction using multi-task deep neural nets and contrastive molecular explanations, Sci. Rep., 13, 4908, 10.1038/s41598-023-31169-8 · DOI
- Gold, 2005, Supplement to the Carcinogenic Potency Database (CPDB): Results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997–1998, Toxicol. Sci., 85, 747, 10.1093/toxsci/kfi161 · DOI
- Veith, 2009, Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries, Nat. Biotechnol., 27, 1050, 10.1038/nbt.1581 · DOI · Paper page
- Yang, 2019, admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties, Bioinformatics, 35, 1067, 10.1093/bioinformatics/bty707 · DOI · Paper page
- Wei, 2022, Interpretable-ADMET: A web service for ADMET prediction and optimization based on deep neural representation, Bioinformatics, 38, 2863, 10.1093/bioinformatics/btac192 · DOI
- Zhang, 2022, HelixADMET: A robust and endpoint extensible ADMET system incorporating self-supervised knowledge transfer, Bioinformatics, 38, 3444, 10.1093/bioinformatics/btac342 · DOI
- Liu, 2021, Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure, Biol. Direct, 16, 6, 10.1186/s13062-020-00285-0 · DOI
- Lim, 2023, Supervised chemical graph mining improves drug-induced liver injury prediction, iScience, 26, 105677, 10.1016/j.isci.2022.105677 · DOI
- Kadioglu, 2021, Selection of safe artemisinin derivatives using a Mach. Learn.-based cardiotoxicity platform and in vitro and in vivo validation, Arch. Toxicol., 95, 2485, 10.1007/s00204-021-03058-4 · DOI
200 of 205 shown
Cited by
A review of large language models and autonomous agents in chemistry
Ramos, M. C., Collison, C. J., & White, A. D. (2025) · Chemical Science · doi:10.1039/d4sc03921a · Cited by 274
Abbas, S. R., Abbas, Z., Zahir, A., & Lee, S. W. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf329 · Cited by 30
Metadata
- Authors
- Han, R., Yoon, H., Kim, G., Lee, H., & Lee, Y.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2023-09-06
- Volume
- 16
- Issue
- 9
- Pages
- 1259
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W4386483965
- Cited by
- 176
- References
- 31
- FWCI
- 23.16
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Research Foundation of Korea (2021M3E5E3080529, 2022R1C1C1007409)
- Chung-Ang University Graduate Research Scholarship in 2023 (2021M3E5E3080529, 2022R1C1C1007409)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. https://app.cochat.ai/papers/10.3390/ph16091259
- The paper
- Han, R., Yoon, H., Kim, G., Lee, H., & Lee, Y. (2023). Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. Pharmaceuticals. https://doi.org/10.3390/ph16091259
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.